A Phase 1 interventional study of Relatlimab and Nivolumab in Advanced Solid Tumors, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Relatlimab · Biological: Nivolumab
Biological: Relatlimab · Biological: Nivolumab
Specified dose on specified days
Also known as: BMS-986016
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Number of Participants with Adverse Events (AEs)
Time frame: Up to 123 Weeks
Number of Participants with Immune-mediated Adverse Events (IMAEs)
Time frame: Up to 123 Weeks
Number of Participants with Serious Adverse Events (SAEs)
Time frame: Up to 123 Weeks
Number of Deaths
Time frame: Up to 123 Weeks
Number of Participants with AEs Leading to Discontinuation
Time frame: Up to 123 Weeks
Number of Participants with Dose-Limiting Toxicities (DLTs)
Time frame: Up to 123 Weeks
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Up to 123 Weeks
Maximum Observed Plasma Concentration (Cmax) of Relatlimab
Time frame: Up to 123 Weeks
Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab
Time frame: Up to 123 Weeks
Trough-observed serum concentration (Ctrough) of Relatlimab
Time frame: Up to 123 Weeks
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
Time frame: Up to 123 Weeks
Disease Control Rate (DCR) per RECIST v1.1 by Investigator
Time frame: Up to 123 Weeks
Duration of Response (DOR) per RECIST v1.1 by Investigator
Time frame: Up to 123 Weeks
Best Overall Response (BOR) per RECIST v1.1 by Investigator
Time frame: Up to 123 Weeks
Ctrough of Nivolumab
Time frame: Up to 123 Weeks
Observed Serum Concentration at End of Infusion (Ceoi) of Nivolumab
Time frame: Up to 123 Weeks
Percentage of Participants Positive for Anti-drug Antibodies (ADAs) to Relatlimab
Time frame: Up to 123 Weeks
Percentage of Participants Positive for ADAs to Nivolumab
Time frame: Up to 123 Weeks
Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Ran from Jul 2022 to primary completion in Jan 2024, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Nivolumab